MSBase

MSBase Registry research articles published in peer-reviewed journals

2023

Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies. Li Y, Saul A, Taylor B, Ponsonby AL, Simpson-Yap S, Blizzard L, Broadley S, Lechner-Scott J; Ausimmune/AusLong Investigators Group; Karabudak R, Patti F, Eichau S, Onofrj M, Ozakbas S, Horakova D, Kubala Havrdova E, Grand'Maison F, Alroughani R, Gerlach O, Amato MP, Altintas A, Girard M, Duquette P, Blanco Y, Ramo-Tello C, Laureys G, Kalincik T, Khoury SJ, Shaygannejad V, Etemadifar M, Singhal B, Mrabet S, Foschi M, Habek M, John N, Hughes S, McCombe P, Ampapa R, van der Walt A, Butzkueven H, de Gans K, McGuigan C, Oreja-Guevara C, Sa MJ, Petersen T, Al-Harbi T, Sempere AP, Van Wijmeersch B, Grigoriadis N, Prevost J, Gray O, Castillo-Triviño T, Macdonell R, Lugaresi A, Sajedi SA; MSBase; van der Mei I. J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980-z. Epub ahead of print. PMID: 37768389.

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. PMID: 37437240; PMCID: PMC10186210.

Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Yamout B, Altintas A, Gerlach O, Lechner-Scott J, Bergamaschi R, Karabudak R, Iuliano G, McGuigan C, Cartechini E, Hughes S, Sa MJ, Solaro C, Kappos L, Hodgkinson S, Slee M, Granella F, de Gans K, McCombe PA, Ampapa R, van der Walt A, Butzkueven H, Sánchez-Menoyo JL, Vucic S, Laureys G, Sidhom Y, Gouider R, Castillo-Trivino T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Al-Harbi TM, Csepany T, Sempere AP, Treviño Frenk I, Stuart EA, Kalincik T. J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331499. doi: 10.1136/jnnp-2023-331499. Epub ahead of print. PMID: 37414534.

Risk of secondary progressive multiple sclerosis after early worsening of disability. Dzau W, Sharmin S, Patti F, Izquierdo G, Eichau S, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Ozakbas S, Gerlach O, Boz C, Grammond P, Terzi M, Amato MP, La Spitaleri D, Ramo-Tello C, Maimone D, Cartechini E, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Iuliano G, Soysal A, Kalincik T. J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331748. doi: 10.1136/jnnp-2023-331748. Epub ahead of print. PMID: 37414538.

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand'Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Triviño TC, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T. Brain. 2023 Jun 27:awad218. doi: 10.1093/brain/awad218. Epub ahead of print. PMID: 37369086.

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Daruwalla C, Shaygannejad V, Ozakbas S, Havrdova EK, Horakova D, Alroughani R, Boz C, Patti F, Onofrj M, Lugaresi A, Eichau S, Girard M, Prat A, Duquette P, Yamout B, Khoury SJ, Sajedi SA, Turkoglu R, Altintas A, Skibina O, Buzzard K, Grammond P, Karabudak R, van der Walt A, Butzkueven H, Maimone D, Lechner-Scott J, Soysal A, John N, Prevost J, Spitaleri D, Ramo-Tello C, Gerlach O, Iuliano G, Foschi M, Ampapa R, van Pesch V, Barnett M, Shalaby N, D'hooghe M, Kuhle J, Sa MJ, Fabis-Pedrini M, Kermode A, Mrabet S, Gouider R, Hodgkinson S, Laureys G, Van Hijfte L, Macdonell R, Oreja-Guevara C, Cristiano E, McCombe P, Sanchez-Menoyo JL, Singhal B, Blanco Y, Hughes S, Garber J, Solaro C, McGuigan C, Taylor B, de Gans K, Habek M, Al-Asmi A, Mihaela S, Castillo Triviño T, Al-Harbi T, Rojas JI, Gray O, Khurana D, Van Wijmeersch B, Grigoriadis N, Inshasi J, Oh J, Aguera-Morales E, Fragoso Y, Moore F, Shaw C, Baghbanian SM, Shuey N, Willekens B, Hardy TA, Decoo D, Sempere AP, Field D, Wynford-Thomas R, Cunniffe NG, Roos I, Malpas CB, Coles AJ, Kalincik T, Brown JWL. Mult Scler. 2023 Jun;29(7):875-883. doi: 10.1177/13524585231151951. Epub 2023 Feb 27. PMID: 36851894.

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis. Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. JAMA Neurol. 2023 Jun 12:e231625. doi: 10.1001/jamaneurol.2023.1625. Epub ahead of print. PMID: 37307006.

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Der Walt AV, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Morgado YB, Spitaleri D, Pesch VV, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H; MSBase Study Group. Neurodegener Dis Manag. 2023 Jun 7. doi: 10.2217/nmt-2023-0005. Epub ahead of print. PMID: 37287269. Epub ahead of print. PMID: 37273217

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. Zhu C, Kalincik T, Horakova D, Zhou Z, Buzzard K, Skibina O, Alroughani R, Izquierdo G, Eichau S, Kuhle J, Patti F, Grand'Maison F, Hodgkinson S, Grammond P, Lechner-Scott J, Butler E, Prat A, Girard M, Duquette P, Macdonell RAL, Weinstock-Guttman B, Ozakbas S, Slee M, Sa MJ, Van Pesch V, Barnett M, Van Wijmeersch B, Gerlach O, Prevost J, Terzi M, Boz C, Laureys G, Van Hijfte L, Kermode AG, Garber J, Yamout B, Khoury SJ, Merlo D, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group. JAMA Neurol. 2023 Jun 5:e231542. doi: 10.1001/jamaneurol.2023.1542. Epub ahead of print. PMID: 37273217

Disability accrual in primary and secondary progressive multiple sclerosis. Harding-Forrester S, Roos I, Nguyen AL, Malpas CB, Diouf I, Moradi N, Sharmin S, Izquierdo G, Eichau S, Patti F, Horakova D, Kubala Havrdova E, Prat A, Girard M, Duquette P, Grand'Maison F, Onofrj M, Lugaresi A, Grammond P, Ozakbas S, Amato MP, Gerlach O, Sola P, Ferraro D, Buzzard K, Skibina O, Lechner-Scott J, Alroughani R, Boz C, Van Pesch V, Cartechini E, Terzi M, Maimone D, Ramo-Tello C, Yamout B, Khoury SJ, La Spitaleri D, Sa MJ, Blanco Y, Granella F, Slee M, Butler E, Sidhom Y, Gouider R, Bergamaschi R, Karabudak R, Ampapa R, Sánchez-Menoyo JL, Prevost J, Castillo-Trivino T, McCombe PA, Macdonell R, Laureys G, Van Hijfte L, Oh J, Altintas A, de Gans K, Turkoglu R, van der Walt A, Butzkueven H, Vucic S, Barnett M, Cristiano E, Hodgkinson S, Iuliano G, Kappos L, Kuhle J, Shaygannejad V, Soysal A, Weinstock-Guttman B, Van Wijmeersch B, Kalincik T; MSBase investigators. J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330726. doi: 10.1136/jnnp-2022-330726. Epub ahead of print. PMID: 37068931.

Comparative effectiveness in multiple sclerosis: A methodological comparison. Roos I, Diouf I, Sharmin S, Horakova D, Havrdova EK, Patti F, Shaygannejad V, Ozakbas S, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Sola P, Ferraro D, Grammond P, Turkoglu R, Buzzard K, Skibina O, Yamou B, Altintas A, Gerlach O, van Pesch V, Blanco Y, Maimone D, Lechner-Scott J, Bergamaschi R, Karabudak R, McGuigan C, Cartechini E, Barnett M, Hughes S, Sa MJ, Solaro C, Ramo-Tello C, Hodgkinson S, Spitaleri D, Soysal A, Petersen T, Granella F, de Gans K, McCombe P, Ampapa R, Van Wijmeersch B, van der Walt A, Butzkueven H, Prevost J, Sanchez-Menoyo JL, Laureys G, Gouider R, Castillo-Triviño T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Deri N, Al-Harbi T, Fragoso Y, Csepany T, Sempere AP, Trevino-Frenk I, Schepel J, Moore F, Malpas C, Kalincik T.  Eur J Neurol. 2023 Apr;30(4):1014-1024. doi: 10.1111/ene.15706. Epub 2023 Feb 16. PMID: 36692895.

External validation of a clinical prediction model in multiple sclerosis  Moradi N, Sharmin S, Malpas CB, Shaygannejad V, Terzi M, Boz C, Yamout B, Khoury SJ, Turkoglu R, Karabudak R, Shalaby N, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T. Mult Scler. 2023 Feb;29(2):261-269. doi: 10.1177/13524585221136036. Epub 2022 Nov 30. PMID: 36448727.

Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Havrdova EK, Patti F, Shaygannejad V, Ozakbas S, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Girard M, Duquette P, Terzi M, Boz C, Grand'Maison F, Hamdy S, Sola P, Ferraro D, Grammond P, Turkoglu R, Buzzard K, Skibina O, Yamout B, Altintas A, Gerlach O, van Pesch V, Blanco Y, Maimone D, Lechner-Scott J, Bergamaschi R, Karabudak R, Iuliano G, McGuigan C, Cartechini E, Barnett M, Hughes S, Sa MJ, Solaro C, Kappos L, Ramo-Tello C, Cristiano E, Hodgkinson S, Spitaleri D, Soysal A, Petersen T, Slee M, Butler E, Granella F, de Gans K, McCombe P, Ampapa R, Van Wijmeersch B, van der Walt A, Butzkueven H, Prevost J, Sinnige LGF, Sanchez-Menoyo JL, Vucic S, Laureys G, Van Hijfte L, Khurana D, Macdonell R, Gouider R, Castillo-Triviño T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Deri N, Al-Harbi T, Fragoso Y, Csepany T, Perez Sempere A, Trevino-Frenk I, Schepel J, Moore F, Kalincik T. Eur J Neurol. 2023 Apr;30(4):1014-1024. doi: 10.1111/ene.15706. Epub 2023 Feb 16. PMID: 36692895.

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, Sørensen PS, Spelman T, van der Walt A, Horakova D, Havrdova E, Girard M, Eichau S, Grand'Maison F, Gerlach O, Terzi M, Ozakbas S, Skibina O, Van Pesch V, Sa MJ, Prevost J, Alroughani R, McCombe PA, Gouider R, Mrabet S, Castillo-Trivino T, Zhu C, de Gans K, Sánchez-Menoyo JL, Yamout B, Khoury S, Sormani MP, Kalincik T, Butzkueven H; Big MS Data Network. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):23-30. doi: 10.1136/jnnp-2022-329987. Epub 2022 Sep 28. PMID: 36171104.

Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity. Spelman T, Horakova D, Ozakbas S, Alroughani R, Onofrj M, Kalincik T, Prat A, Terzi M, Grammond P, Patti F, Csepany T, Boz C, Lechner-Scott J, Granella F, Grand'Maison F, van der Walt A, Zhu C, Butzkueven H; MSBase Study Group. Mult Scler Relat Disord. 2023 Feb;70:104477. doi: 10.1016/j.msard.2022.104477. Epub 2022 Dec 23. PMID: 36746088.

2021

Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Kenney R, Liu M, Patil S, Alroughani R, Ampapa R, Bergamaschi R, Boz C, Butzkueven H, Gomez JC, Cartechini E, Madueño SE, Ferraro D, Grand-Maison F, Granella F, Horakova D, Izquierdo Ayuso G, Kalincik T, Lizrova Preiningerova J, Lugaresi A, Onofrj M, Ozakbas S, Patti F, Sola P, Soysal A, Spitaleri DLA, Terzi M, Turkoglu R, van Pesch V, Saidha S, Thorpe LE, Galetta SL, Balcer LJ, Kister I, Spelman T; MSBase Study Group. J Neurol Sci. 2021 Nov 15;430:118067. doi: 10.1016/j.jns.2021.118067. Epub 2021 Sep 3. PMID: 34537678.

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frénay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pfleger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T; Danish Multiple Sclerosis Registry, OFSEP and the MSBase investigators. CNS Drugs. 2021 Nov;35(11):1217-1232. doi: 10.1007/s40263-021-00860-7. Epub 2021 Sep 18. PMID: 34536228.

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. Barnett M, Bergsland N, Weinstock-Guttman B, Butzkueven H, Kalincik T, Desmond P, Gaillard F, van Pesch V, Ozakbas S, Rojas JI, Boz C, Altintas A, Wang C, Dwyer MG, Yang S, Jakimovski D, Kyle K, Ramasamy DP, Zivadinov R. Neuroimage Clin. 2021;32:102802. doi: 10.1016/j.nicl.2021.102802. Epub 2021 Aug 24. PMID: 34469848; PMCID: PMC8408519.

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño SE, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C, Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas C, Butzkueven H, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups. Neurology. 2021 Aug 31;97(9):e869-e880. doi: 10.1212/WNL.0000000000012354. Epub 2021 Jun 30. PMID: 34193589.

Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. Moradi N, Sharmin S, Malpas C, Ozakbas S, Shaygannejad V, Terzi M, Boz C, Yamout B, Turkoglu R, Karabudak R, Hamdy S, Soysal A, Altıntaş A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T; MSBase Study Group. CNS Drugs. 2021 Oct;35(10):1097-1106. doi: 10.1007/s40263-021-00833-w. Epub 2021 Jun 23. PMID: 34164782.

Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]. De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand'Maison F, Bergamaschi R, Sá MJ, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L. Comput Methods Programs Biomed. 2022 Jan;213:106479. doi: 10.1016/j.cmpb.2021.106479. Epub 2021 Nov 5. Erratum for: Comput Methods Programs Biomed. 2021 Sep;208:106180. PMID: 34749246.

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Andersen JB, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Sørensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Skibina O, Solaro C, Karabudak R, Wijmeersch BV, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, Sèze JD, Maillart E, Zephir H, Labauge P, Defer G, Lebrun C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Marousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Leray E, Laplaud DA, Butzkueven H, Kalincik T, Vukusic S, Magyari M. Mult Scler Relat Disord. 2021 Aug;53:103012. doi: 10.1016/j.msard.2021.103012. Epub 2021 May 8. PMID: 34116480.

The MSBase pregnancy, neonatal outcomes, and women’s health registry. Jokubaitis, VG. Skibina, O. Alroughani, R. Altintas, A. Butzkueven, H. Eichau, S. Fragoso, Y. Hellwig, K. Hughes, S. Rath, L. Van der Walt, A. Gray, O. Ther Adv Neurol Disord. (Apr 2021) 14: 1-8. doi: 10.1177/17562864211009104.

Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. Yeh, W.Z. Widyastuti, P.A. Van der Walt, A. Stankovich, J. Havrdova, E. Horakova, D. Vodehnalova, K. Ozakbas, S. Eichau, S. Duquette, P. Kalincik, T. Patti, F. Boz, C. Terzi, M. Yamout, B.I. Lechner-Scott, J. Sola, P. Skibina, O.G. Barnett, M. Onofrj, M. José Sá, M. McCombe, P. Grammond, P. Ampapa, R. Grand'Maison, F. Bergamaschi, R. Spitaleri, D. Van Pesch, V. Cartechini, E. Hodgkinson, S. Soysal, A. Saiz, A. Gresle, M. Uher, T. Maimone, D. Turkoglu, R. Hupperts, R. Amato, MP. Granella, F. Oreja-Guevara, C. Altintas, A. Macdonell, R. Castillo-Trivino, T. Butzkueven, H. Alroughani, R. Jokubaitis, V.G. and the MSBase Study Group. doi: 10.1212/WNL.0000000000012084. [Online ahead of print – Apr 2021].

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. Butzkueven, H. Spelman, T. Horakova, D. Hughes, S. Solaro, C. Izquierdo, G. Havrdová, E.K. Grand'Maison, F. Prat, A. Girard, M. Hupperts, R. Onofrj, M. Lugaresi, A. Taylor, B. and the MSBase Study Group. Giovannoni, G. Kappos, L. Hauser, S.L. Montalban, X. Craveiro, L. Freitas, R. Model, F. Overell, J. Muros‐Le Rouzic, E. Sauter, A. Wang, Q. Wormser, D. Wolinsky, J.S. J. Neurol. doi: 10.1111/ene.14824. [Online ahead of print – Mar 2021].

Determinants of therapeutic lag in multiple sclerosis. Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Debouverie, M. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Edan, G. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugaresi, A. Grammond, P. Ciron, J. Ruet, A. Ozakbas, S. De Seze, J. Louapre, C. Zephir, H. Sá, MJ. Sola, P. Ferraro, D. Labauge, P. Defer, G. Bergamaschi, R. Lebrun-Frenay, C. Boz, C. Cartechini, E. Moreau, T. Laplaud, D. Lechner-Scott, J. Grand'Maison, F. Gerlach, O. Terzi, M. Granella, F. Alroughani, R. Iuliano, G. Van Pesch, V. Van Wijmeersch, B. Spitaleri, D. Soysal, A. Berger, E. Prevost, J. Aguera-Morales, E. McCombe, P. Castillo Triviño, T. Clavelou, P. Pelletier, J. Turkoglu, R. Stankoff, B. Gout, O. Thouvenot, E. Heinzlef, O. Sidhom, Y. Gouider, R. Csepany, T. Bourre, B. Al Khedr, A. Casez, O. Cabre, P. Montcuquet, A. Wahab, A. Camdessanche, JP. Maurousset, A. Patry, I. Hankiewicz, K. Pottier, C. Maubeuge, N. Labeyrie, C. Nifle, C. Coles, A. Malpas, CB. Vukusic, S. Butzkueven, H. Kalincik, T. Mult Scler. doi: 10.1177/1352458520981300. [Online ahead of print – Jan 2021]. PMID: 33423618

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Kalincik, T. Diouf, I. Sharmin, S. Malpas, C. Spelman, T. Horakova, D. Havrdova, EK. Trojano, M. Izquierdo, G. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Jokubaitis, V. van der Walt, A. Grand'Maison, F. Sola, P. Ferraro, D. Shaygannejad, V. Alroughani, R. Hupperts, R. Terzi, M. Boz, C. Lechner-Scott, J. Pucci, E. Van Pesch, V. Granella, F. Bergamaschi. R. Spitaleri. D. Slee. M. Vucic. S. Ampapa, R. McCombe, P. Ramo-Tello, C. Prevost, J. Olascoaga, J. Cristiano, E. Barnett, M. Saladino, ML. Sanchez-Menoyo, JL. Hodgkinson, S. Rozsa, C. Hughes, S. Moore, F. Shaw, C. Butler, E. Skibina, O. Gray, O. Kermode, A. Csepany, T. Singhal, B. Shuey, N. Piroska, I. Taylor, B. Simo, M. Sirbu, CA. Sas, A. Butzkueven, H.; MSBase Study group. Neurology. (Feb 2021) 96(5): e783-e797. doi: 10.1212/WNL.0000000000011242.

2020

Treatment response score to glatiramer acetate or interferon beta-1a. Bovis, F. Kalincik, T. Lublin, F. Cutter, G. Malpas, C. Horakova, D. Havrdova, EK. Trojano, M. Prat, A. Girard, M. Duquette, P. Onofrj, M. Lugaresi, A. Izquierdo, G. Eichau, S. Patti, F. Terzi, M. Grammond, P. Bergamaschi, R. Sola, P. Ferraro, D. Ozakbas, S. Iuliano, G. Boz, C. Hupperts, R. Grand'Maison, F. Oreja-Guevara, C. van Pesch, V. Cartechini, E. Petersen, T. Altintas, A. Soysal, A. Ramo-Tello, C. McCombe, P. Turkoglu, R. Butzkueven, H. Wolinsky, JS. Solaro, C. Sormani, MP. Neurology. doi: 10.1212/WNL.0000000000010991 [Online ahead of print – Oct 2020].

Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Roos, I. Leray, E. Frascoli, F. Casey, R. Brown, JWL. Horakova, D. Havrdova, EK. Trojano, M. Patti, F. Izquierdo, G. Eichau, S. Onofrj, M. Lugaresi, A. Prat, A. Girard, M. Grammond, P. Sola, P. Ferraro, D. Ozakbas, S. Bergamaschi, R. Sá, MJ. Cartechini, E. Boz, C. Granella, F. Hupperts, R. Terzi, M. Lechner-Scott, J. Spitaleri, D. Van Pesch, V. Soysal, A. Olascoaga, J. Prevost, J. Aguera-Morales, E. Slee, M. Csepany, T. Turkoglu, R. Sidhom, Y. Gouider, R. Van Wijmeersch, B. McCombe, P. Macdonell, R. Coles, A. Malpas, CB. Butzkueven, H. Vukusic, S. Kalincik, T.; MSBase; OFSEP investigators. Brain. (Sept 2020) 143(9): 2742-2756. 10.1093/brain/awaa231

Association of Pregnancy With the Onset of Clinically Isolated Syndrome. Nguyen, A. Vodehnalova, K. KalinciK, T. Signori, A. Havrdova, E.K. Lechner-Scott, J. Skibina, O.G. Eastaugh, A. Taylor, L. Baker, J. McGuinn, N. Rath, L. Maltby, V. Sormani, MP. Butzkueven, H. Van der Walt, A. Horakova, D. Jokubaitis, V.G. JAMA Neurol. doi: 10.1001/jamaneurol.2020.3324. [Online ahead of print – Sept 2020].

Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis. Lizak, N.  Malpas,^, C.B. Sharmin, S. Havrdova, E.K.  Horakova, D.  Izquierdo, G. ^,  Eichau, S. Lugaresi, A. Duquette, P. Girard, M. Prat, A. Larochelle, C. Trojano, M. Grand'Maison, F. Grammond, P.  Sola, P. Ferraro, D.  Hupperts, R. Bergamaschi, R. Boz, C. Van Pesch, V. Spitaleri, D. Terzi, M.  Kalincik, T.  MSBase Study Group.  JAMA Neurol. https://pubmed.ncbi.nlm.nih.gov/32716480/ [Online ahead of print – Jul 2020].

Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Kunchok, A. Lechner-Scott, J. Granella, F. Trojano, M. Alroughani, R. Sola, P. Ferraro, D. Lugaresi, A. Onofrj, M. Ozakbas, S. Izquierdo, G. Grammond, P. Luis Sanchez-Menoyo, J. Van Wijmeersch, B. Boz, C. Pucci, E. McCombe, P. Grand'Maison, F. Spitaleri, D. Vucic, S. Hupperts, R. Jokubaitis, V. Sormani, MP. Butzkueven, H. Kalincik, T.; MSBase Study Group. Mult Scler. https://doi: 10.1177/1352458520936823. [Online ahead of print – Jul 2020].

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Le, M. Malpas, C. Sharmin, S. Horáková, D. Havrdova, E. Trojano, M. Izquierdo, G. Eichau, S. Ozakbas, S. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Larochelle, C. Alroughani, R. Bergamaschi, R. Sola, P. Ferraro, D. Grammond, P. Grand' Maison, F. Terzi, M. Boz, C. Hupperts, R. Butzkueven, H. Pucci, E. Granella, F. Van Pesch, V. Soysal, A. Yamout, BI. Lechner-Scott, J. Spitaleri, D. Ampapa, R. Turkoglu, R. Iuliano, G. Ramo-Tello, C. Sanchez-Menoyo, JL. Sidhom, Y. Gouider, R. Shaygannejad, V. Prevost, J. Altintas, A. Fragoso, YD. McCombe, PA. Petersen, T. Slee, M. Barnett, MH. Vucic, S. Van Der Walt, A. Kalincik, T. Mult Scler. https://doi/10.1177/1352458520926955 [Online ahead of print – Jun 2020].

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Lizak, N. Hodgkinson, S. Butler, E. Lechner-Scott, J. Slee, M. McCombe, PA. Shaw, C. Skibina, O. Vucic, S. Shuey, N. Barnett, MH. Parratt, J. Butzkueven, H. Jack, D. Fabris, J. Kalincik, T. Mult Scler. https://doi.org/10.1177/1352458520921087 [Online ahead of print – Jun 2020].

Early clinical markers of aggressive multiple sclerosis. Malpas, CB. Manouchehrinia, A. Sharmin, S. Roos, I. Horakova, D. Havrdova, EK. Trojano, M. Izquierdo, G. Eichau, S. Bergamaschi, R. Sola, P. Ferraro, D. Lugaresi, A. Prat, A. Girard, M. Duquette, P. Grammond, P. Grand'Maison, F. Ozakbas, S. Van Pesch, V. Granella, F. Hupperts, R. Pucci, E. Boz, C. Sidhom, Y. Gouider, R. Spitaleri, D. Soysal, A. Petersen, T. Verheul, F. Karabudak, R. Turkoglu, R. Ramo-Tello, C. Terzi, M. Cristiano, E. Slee, M. McCombe, P. Macdonell, R. Fragoso, Y. Olascoaga, J. Altintas, A. Olsson, T. Butzkueven, H. Hillert, J. Kalincik, Brain. (May 2020) 143(5): 1400-1413. http://doi.org/10.1093/brain/awaa081 

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observation cohort study. He, A. Merkel, B. Brown, JWL. Zhovits Ryerson, L. Kister, I. Malpas, CB. Sharmin, S. Horakova, D. Kubala Havrdova, E. Spelman, T. Izquierdo, G. Eichau, S. Trojano, M. Lugaresi, A. Hupperts, R. Sola, P. Ferraro, D. Lycke, J. Grand'Maison, F. Prat, A. Girard, M. Duquette, P. Larochelle, C. Svenningsson, A. Petersen, T. Grammond, P. Granella, F. Van Pesch, V. Bergamaschi, R. McGuigan, C. Coles, A. Hillert, J. Piehl, F. Butzkueven, H. Kalincik, T; MSBase study group. Lancet Neurol. (Apr. 2020) 19(4):307-316. https://doi.org/10.1016/S1474-4422(20)30067-3.

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Kunchok, A. Malpas, C. Nytrova, P. Havrdova, EK. Alroughani, R. Terzi, M. Yamout, B. Hor, JY. Karabudak, R. Boz, C. Ozakbas, S. Olascoaga, J. Simo, M. Granella, F. Patti, F. McCombe, P. Csepany, T. Singhal, B. Bergamaschi, R. Fragoso, Y. Al-Harbi, T. Turkoglu, R. Lechner-Scott, J. Laureys, G. Oreja-Guevara, C. Pucci, E. Sola, P. Ferraro, D. Altintas, A. Soysal, A. Vucic, S. Grand'Maison, F. Izquierdo, G. Eichau, S. Lugaresi, A. Onofrj, M. Trojano, M. Marriott, M. Butzkueven, H. Kister, I. Kalincik, T. Mult Scler Relat Disord. http://dx.doi.org/10.1016/j.msard.2019.101868 [Epub ahead of print].

Risk of secondary progressive multiple sclerosis: A longitudinal study. Fambiatos, A. Jokubaitis, V. Horakova, D. Kubala Havrdova, E. Trojano, M. Prat, A. Girard, M. Duquette, P. Lugaresi, A. Izquierdo, G. Grand'Maison, F. Grammond, P. Sola, P. Ferraro, D. Alroughani, R. Terzi, M. Hupperts, R. Boz, C. Lechner-Scott, J. Pucci, E. Bergamaschi, R. Van Pesch, V. Ozakbas, S. Granella, F. Turkoglu, R. Iuliano, G. Spitaleri, D. McCombe, P. Solaro, C. Slee, M. Ampapa, R. Soysal, A. Petersen, T. Sanchez-Menoyo, JL. Verheu, F. Prevost, J. Sidhom, Y. Van Wijmeersch, B. Vucic, S. Cristiano, E. Saladino, ML. Deri, N. Barnett, M. Olascoaga, J. Moore, F. Skibina, O. Gray, O. Fragoso, Y. Yamout, B. Shaw, C. Singhal, B. Shuey, N. Hodgkinson, S. Altintas, A. Al-Harbi, T. Csepany, T. Taylor, B. Hughes, J. Jun, JK. van der Walt, A. Spelman, T. Butzkueven, H. Kalincik, T. Mult Scler. (Jan 2020) 26(1): 79-90 https://doi.org/10.1177/1352458519868990

2018

Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis. Hughes, J., V. Jokubaitis, A. Lugaresi, R. Hupperts, G. Izquierdo, A. Prat, M. Girard, P. Duquette, F. Grand’Maison, P. Grammond, P. Sola, D. Ferraro, C. Ramo-Tello, M. Trojano, M. Slee, V. Shaygannejad, C. Boz, J. Lechner-Scott, V. Van Pesch, E. Pucci, C. Solaro, F. Verheul, M. Terzi, F. Granella, D. Spitaleri, R. Alroughani, J. K. Jun, A. Fambiatos, A. Van der Walt, H. Butzkueven, T. Kalincik, on behalf of the MSBase Study Group. JAMA Neurol. (Nov 2018) 1;75(11):1407-1415. http://dx.doi.org/10.1001/jamaneurol.2018.2109 

Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis. Min, M., T. Spelman, A. Lugaresi, C. Boz, D. Spitaleri, E. Pucci, F. Grand’Maison, F. Granella, G. Izquierdo, H. Butzkueven, J. L. Sanchez-Menoyo, M. Barnett, M. Girard, M. Trojano, P. Grammond, P. Duquette, P. Sola, R. Alroughani, R. Hupperts, S. Vucic, T. Kalincik, V. Van-Pesch and J. Lechner-Scott Mult Scler. (Oct 2018) 24(12): 1569-1577 http://dx.doi.org/10.1177/1352458518798147 

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Kalincik, T., V. Jokubaitis, T. Spelman, D. Horakova, E. Havrdova, M. Trojano, J. Lechner-Scott, A. Lugaresi, A. Prat, M. Girard, P. Duquette, P. Grammond, C. Solaro, F. Grand'Maison, R. Hupperts, J. Prevost, P. Sola, D. Ferraro, M. Terzi, E. Butler, M. Slee, A. Kermode, M. Fabis-Pedrini, P. McCombe, M. Barnett, C. Shaw, S. Hodgkinson, H. Butzkueve, on behalf of the MSBase Study Group. Mult. Scler. (Oct 2018) 24(12):1617-1626. http://dx.doi.org/10.1177/1352458517728812

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Kister, I., T. Spelman, F. Patti, P. Duquette, M. Trojano, G. Izquierdo, A. Lugaresi, P. Grammond, P. Sola, D. Ferraro, F. Grand’Maison, R. Alroughani, M. Terzi, C. Boz, R. Hupperts, J. Lechner-Scott, L. Kappos, E. Pucci, S. Hodgkinson, C. Solaro, H. Butzkueven. J Neurol Sci (Aug 2018) 391: 72-76. http://dx.doi.org/10.1016/j.jns.2018.06.001

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Signori, A., G. Izquierdo, A. Lugaresi, R. Hupperts, F. Grand’Maison, P. Sola, D. Horakova, E. Havrdova, A. Prat, M. Girard, P. Duquette, C. Boz, P. Grammond, M. Terzi, B. Singhal, R. Alroughani, T. Petersen, C. Ramo, C. Oreja-Guevara, D. Spitaleri, V. Shaygannejad, H. Butzkueven, T. Kalincik, V. Jokubaitis, M. Slee, R. Fernández Bolaños , J. L. Sanchez-Menoyo, E. Pucci, F. Granella, J. Lechner-Scott, G. Iuliano, S. Hughes, R. Bergamaschi, B. Taylor, F. Verheul, M. Edite Rio, M.P. Amato, S.A. Sajedi, N. Majdinasab, V. Van Pesch, M.P. Sormani, M. Trojano. Mult Scler. (Apr 2018) 24(5): 642-652.  http://dx.doi.org/10.1177/1352458517703800

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Fragoso, Y. D., T. Spelman, C. Boz, R. Alroughani, A. Lugaresi, S. Vucic, H. Butzkueven, M. Terzi, E. Havrdova, D. Horakova, F. Granella, J. Olascoaga, J. L. Sanchez-Menoyo, E. Pucci, M. Barnett, J. B. B. Brooks, J. Haartsen, on behalf of the MSBase Lymphopenia and Efficacy of Fingolimod Sub-Study Investigators. Mult Scler Relat Disord. (Jan 2018) 19: 105-108. http://dx.doi.org/10.1016/j.msard.2017.11.018

2016

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Tao, C., S. Simpson Jr, I. van der Mei, L. Blizzard, E. Havrdova, D. Horakova, V. Shaygannejad, A. Lugaresi, G. Izquierdo, M. Trojano, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, R. Alroughani, M. Terzi, C. Oreja-Guevara, S.A. Sajedi, G. Iuliano, P. Sola, J. Lechner-Scott, V. Van Pesch, E. Pucci, R. Bergamaschi, M. Barnett, C. Ramo, B. Singhal, D. LA Spitaleri, M. Slee, F. Verheul, R. Fernández Bolaños, M.P. Amato, E. Cristiano, F. Granella, S. Hodgkinson, M. Fiol, O. Gray, P. McCombe, M.L. Saladino, J.L. Sanchez Menoyo, N. Shuey, S. Vucic, C. Shaw, N. Deri, W. Oleschko-Arruda, H. Butzkueven, T. Spelman, B.V. Taylor on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Dec 2016) 87(12):1343-1349. http://dx.doi.org/10.1136/jnnp-2016-314013

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Kister, I., T. Spelman, R. Alroughani, J. Lechner-Scott, P. Duquette, F. Grand’Maison, M. Slee, A. Lugaresi, M. Barnett, P. Grammond, G. Iuliano, R. Hupperts, E. Pucci, M. Trojano, H. Butzkueven on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Oct 2016) 87(10):1133-7. http://dx.doi.org/10.1136/jnnp-2016-313760

Defining secondary progressive multiple sclerosis. Lorscheider , J., K. Buzzard, V. Jokubaitis, T. Spelman, E. Havrdova, D. Horakova, M. Trojano, G. Izquierdo, M. Girard, P. Duquette, A. Prat, A. Lugaresi, F. Grand’Maison, P. Grammond, R. Hupperts, R. Alroughani, P. Sola, C. Boz, E. Pucci, J. Lechner-Scott, R. Bergamaschi, C. Oreja-Guevara, G. Iuliano, V. Van Pesch, F. Granella, C. Ramo-Tello, D. Spitaleri, T. Petersen, M. Slee, F. Verheul, R. Ampapa, MP. Amato, P. McCombe, S. Vucic, JL. Sanchez Menoyo, E. Cristiano, MH. Barnett, S. Hodgkinson, J. Olascoaga, ML. Saladino, O. Gray, C. Shaw, F. Moore, H. Butzkueven, T. Kalincik on behalf of the MSBase Study Group. Brain. (Sep 2016) 139(Pt 9):2395-405. http://dx.doi.org/10.1093/brain/aww173

Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Kister, I., T. Spelman, R. Alroughani, J. Lechner-Scott, P. Duquette, F. Grand’Maison, M. Slee, A. Lugaresi, M. Barnett, P. Grammond, G. Iuliano, R. Hupperts, E. Pucci, M. Trojano and H. Butzkueven, on behalf of the MSBase Study Group. Ann Neurol. (Jul 2016) 80(1):89-100. http://dx.doi.org/10.1002/ana.24682

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS. Jokubaitis, V.G., T. Spelman, T. Kalincik, J. Lorscheider, E. Havrdova, D. Horakova, P. Duquette, M. Girard, A. Prat, G. Izquierdo, P. Grammond, V. Van Pesch, E. Pucci, F. Grand’Maison, R. Hupperts, F. Granella, P. Sola, R. Bergamaschi, G. Iuliano, D. Spitaleri, C. Boz, S. Hodgkinson, J. Olascoaga, F. Verheul, D. Paolicelli, H. Butzkueven, A. Lugaresi and M. Trojano, for the MSBase Study Group. Neurol Clin Pract. (Apr 2016) 6(2):102-115. http://dx.doi.org/10.1212/CPJ.0000000000000227

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman, T., L. Mekhael, T. Burke, H. Butzkueven, S. Hodgkinson, E. Havrdova, D. Horakova, P. Duquette, G. Izquierdo, F. Grand’Maison, P. Grammond, M. Barnett, J. Lechner-Scott, R. Alroughani, M. Trojano, A. Lugaresi, F. Granella, E. Pucci and S. Vucic on behalf of the MSBase Study Group. Eur J Neurol. (Apr 2016) 23(4):729-736. http://dx.doi.org/10.1111/ene.12929

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Warrender-Sparkes, M., T. Spelman, G. Izquierdo, M. Trojano, A. Lugaresi, F. Grand’Maison, E. Havrdova, D. Horakova, C. Boz, C. Oreja-Guevara, R. Alroughani, G. Iuliano, P. Duquette, M. Girard, M. Terzi, R. Hupperts, P. Grammond, T. Petersen, R. Fernández Bolaños, M. Fiol, E. Pucci, J. Lechner-Scott, F. Verheul, E. Cristiano, V. Van Pesch, T. Petkovska-Boskova, F. Moore, I. Kister, R. Bergamaschi, M. L. Saladino, M. Slee, M. Barnett, M. P. Amato, C. Shaw, N. Shuey, C. Young, O. Gray, L. Kappos, H. Butzkeven, T. Kalincik and V. Jokubaitis, on behalf of the MSBase study group. Mult Scler. (Apr 2016) 22(4):520-532. http://dx.doi.org/10.1177/1352458515594041

2014

Seasonal variation of relapse rate in multiple sclerosis is latitude-dependent. Spelman, T., O. Gray, M. Trojano, T. Petersen, G. Izquierdo, A. Lugaresi, R. Hupperts, R. Bergamaschi, P. Duquette, P. Grammond, G. Giuliani, C. Boz, F. Verheul, C. Oreja-Guevara, M. Barnett, F. Grand’Maison, M. E. Rio, J. Lechner-Scott, V. Van Pesch, R. Fernández Bolaños, S. Flechter, L. Den Braber-Moerland, G. Iuliano, M. P. Amato, M. Slee, E. Cristiano, M.L. Saladino, M. Paine, N. Vella, K. Kasa, N. Deri, J. Herbert, F. Moore, T. Petkovska-Boskova, R. Alroughani, A. Savino, C. Shaw, S. Vucic, V. Santiago, E. A. Bacile, E. Skromne, D. Poehlau, J. A. Cabrera-Gomez, R. Lucas and H. Butzkueven. Ann Neurol. (Dec 2014) 76(6):880-90. http://dx.doi.org/10.1002/ana.24287

Risk of relapse phenotype recurrence in multiple sclerosis. Kalincik, T., K. Buzzard, V. G. Jokubaitis, M. Trojano, P. Duquette, I. Guillermo, M. Girard, A. Lugaresi, P. Grammond, F. Grand’Maison, C. Oreja-Guevara, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, G. Iuliano, J. Lechner-Scott, M. Barnett, R. Bergamaschi, V. Van Pesch, M. P. Amato, E. van Munster, R. Fernandez-Bolanos, F. Verheul, M. Fiol, E. Cristiano, M. Slee, M. E. Rio, D. L. A. Spitaleri, R. Alroughani, O. Gray, M. L. Saladino, S. Flechter, J. Herbert, J. A. Cabrera- Gomez, N. Vella, M. Paine, C. Shaw, F. Moore, S. Vucic, A. Savino, B. Singhal, T. Pekovska-Boskova, J. Parratt, C-A. Sirbu, C. Rozsa, D. Liew, H. Butzkueven, on behalf of the MSBase study group. Mult Scler. (Oct 2014) 20(11):1511-22. http://dx.doi.org/10.1177/1352458514528762

Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Hughes, S. E., T. Spelman, O. M. Gray, C. Boz, M. Trojano, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand’Maison, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, G. Giuliani, J. Lechner-Scott, M. Barnett, M. E. Rio, V. van Pesch, M. P. Amato, G. Iuliano, M. Slee, F. Verheul, E. Cristiano, R. Fernandez-Bolanos, D. Poehlau, M. L. Saladino, N. Deri, J. Cabrera-Gomez, N. Vella, J. Herbert, E. Skromne, A. Savino, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, G. McDonnell, S. A. Hawkins, F. Kee, H. Butzkueven on behalf of the MSBase study group. Mult Scler. (May 2014) 20(6):739-46. http://dx.doi.org/10.1177/1352458513507816

Fingolimod after natalizumab and the risk of short-term relapse. Jokubaitis, V. G., V. Li, T. Kalincik, G. Izquierdo, S. Hodgkinson, R. Alroughani, J. Lechner-Scott, A. Lugaresi, P. Duquette, M. Girard, M. Barnett, F. Grand’Maison, M. Trojano, M. Slee, G. Giuliani, C. Shaw, C. Boz, D. L. A. Spitaleri, F. Verheul, J. Haartsen, D. Liew, H. Butzkueven on behalf of the MSBase study group. Neurology. (Apr 2014) 82(14):1204-11. http://dx.doi.org/10.1212/WNL.0000000000000283

2012

Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. Trojano, M., G. Lucchese, G. Graziano, B. V. Taylor, S. Simpson, Jr., V. Lepore, F. Grand'Maison, P. Duquette, G. Izquierdo, P. Grammond, M. P. Amato, R. Bergamaschi, G. Giuliani, C. Boz, R. Hupperts, V. Van Pesch, J. Lechner-Scott, E. Cristiano, M. Fiol, C. Oreja-Guevara, M. L. Saladino, F. Verheul, M. Slee, D. Paolicelli, C. Tortorella, M. D'Onghia, P. Iaffaldano, V. Direnzo, H. Butzkueven on behalf of the MSBase Study Group, the New Zealand MS Prevalence Study Group. PLoS One. (Oct 2012) 7(10):e48078. http://dx.doi.org/10.1371/journal.pone.0048078

Increasing age at disability milestones among MS patients in the MSBase registry. Kister, I., E. Chamot, G. Cutter, T. E. Bacon, V. G. Jokubaitis, S. E. Hughes, O. M. Gray, M. Trojano, G. Izquierdo, F. Grand'Maison, P. Duquette, A. Lugaresi, P. Grammond, C. Boz, R. Hupperts, T. Petersen, G. Giuliani, C. Oreja- Guevara, G. Iuliano, J. Lechner-Scott, R. Bergamaschi, M. E. Rio, F. Verheul, M. Fiol, V. Van Pesch, M. Slee, H. Butzkueven, J. Herbert and MSBase Investigators. J Neurol Sci. (Jul 2012) 318(1-2):94-9. http://dx.doi.org/10.1016/j.jns.2012.03.017

The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Lechner-Scott, J., B. Spencer, T. de Malmanche, J. Attia, M. Fitzgerald, M. Trojano, F. Grand'Maison, J. A. C. Gomez, G. Izquierdo, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, C. Boz, G. Giuliani, V. Van Pesch, G. Iuliano, M. Fiol, E. Cristiano, F. Verheul, M. L. Saladino, M. Slee, M. Barnett, N. Deri, S. Flechter, N. Vella, C. Shaw, J. Herbert, F. Moore, T. Petkovska-Boskova, V. Jokubaitis, H. Butzkueven for the MSBase study group. Mult Scler. (Jul 2012) 18(7):974-82. http://dx.doi.org/10.1177/1352458511431729

Country, Sex, Edss Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. Meyniel, C., T. Spelman, V. G. Jokubaitis, M. Trojano, G. Izquierdo, F. Grand'Maison, C. Oreja-Guevara, C. Boz, A. Lugaresi, M. Girard, P. Grammond, G. Iuliano, M. Fiol, J. A. Cabrera-Gomez, R. Fernández Bolaños, G. Giuliani, J. Lechner-Scott, E. Cristiano, J. Herbert, T. Petkovska-Boskova, R. Bergamaschi, V. Van Pesch, F. Moore, N. Vella, M. Slee, V. Santiago, M. Barnett, E. Havrdova, C. Young, C-A. Sirbu, M. Tanner, M. Rutherford, H. Butzkueven, on behalf of the MSBasis Study Group. PLoS One. (Jun 2012) 7(6):e38661. http://dx.doi.org/10.1371/journal.pone.0038661

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase registry. Hughes, S., T. Spelman, M. Trojano, A. Lugaresi, G. Izquierdo, F. Grand'Maison, P. Duquette, M. Girard, P. Grammond, C. Oreja-Guevara, R. Hupperts, C. Boz, R. Bergamaschi, G. Giuliani, M. E. Rio, J. Lechner-Scott, V. van Pesch, G. Iuliano, M. Fiol, F. Verheul, M. Barnett, M. Slee, J. Herbert, I. Kister, N. Vella, F. Moore, T. Petkovska-Boskova, V. Shaygannejad, V. Jokubaitis, G. McDonnell, S. Hawkins, F. Kee, O. Gray, H. Butzkueven on behalf of the MSBase Study Group. J Neurol Neurosurg Psychiatry. (Mar 2012) 83(3):305-10. http://dx.doi.org/10.1136/jnnp-2011-301051